Review article
https://doi.org/10.22514/SV142.102018.12
Levodopa-carbidopa-entacapone overdose presenting as altered mental status, xanthoderma, and yellowish sclera
SEONG JONG YUN
; Department of Radiology Kyung Hee University Hospital at Gangdong Kyung Hee University School of Medicine 892 Dongnam-ro, Gangdong-gu Seoul, 05278, Republic of Korea
SUN HWA LEE
SEOKYONG RYU
SEUNG WOON CHOI
HYE JIN KIM
TAE KYUNG KANG
SUNG CHAN OH
SUK JIN CHO
Abstract
Levodopa-carbidopa-entacapone is a single combination drug consisting of levodopa (aromatic amino acid), carbidopa (dopa-decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase inhibitor). The Food and Drug Administration approved levodopa-carbidopa-entacapone in 2003, as treatment for idiopathic Parkinson’s disease in patients experiencing signs and symptoms of wearing-off. Although various adverse drug reactions of levodopa-carbidopa-entacapone have been recorded, there has been no reported case of levodopa-carbidopa-entacapone overdose. We report the first case of signs and symptoms of an overdose of levodopa-carbidopa-entacapone (levodopa: 3000 mg; carbidopa: 750 mg; entacapone: 6000 mg) in a suicide attempt, presenting as altered mentality, xanthoderma, and yellowish sclera without hyperbilirubinemia.
Keywords
levodopa-carbidopa-entacapone; Parkinson’s disease; drug overdose; xanthoderma; yellowish sclera; toxicology
Hrčak ID:
217608
URI
Publication date:
1.11.2018.
Visits: 1.697 *